XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells
Cell Reports · 2024-02 · 43 (2) · 113600
DOI: 10.1016/j.celrep.2023.113600 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024-02. Verfasst von Tao Zou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, M…. Hauptthemen laut MEDLINE: Interferons, Neoplasms. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, American Society of Clinical Oncology.
Abstract (Originalsprache)
Emerging data suggest that induction of viral mimicry responses through activation of double-stranded RNA (dsRNA) sensors in cancer cells is a promising therapeutic strategy. One approach to induce viral mimicry is to target molecular regulators of dsRNA sensing pathways. Here, we show that the exoribonuclease XRN1 is a negative regulator of the dsRNA sensor protein kinase R (PKR) in cancer cells with high interferon-stimulated gene expression. XRN1 deletion causes PKR pathway activation and consequent cancer cell lethality. Disruption of interferon signaling with the JAK1/2 inhibitor ruxolitinib can decrease cellular PKR levels and rescue sensitivity to XRN1 deletion. Conversely, interferon-β stimulation can increase PKR levels and induce sensitivity to XRN1 inactivation. Lastly, XRN1 deletion causes accumulation of endogenous complementary sense/anti-sense RNAs, which may represent candidate PKR ligands. Our data demonstrate how XRN1 regulates PKR and how this interaction creates a vulnerability in cancer cells with an activated interferon cell state.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Cancer Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Genetics, Harvard Medical School, Boston,…
Förderung
- NCI NIH HHS
- National Cancer Institute
- American Society of Clinical Oncology
- National Institutes of Health
- Pharmaceuticals Bayer
- American Cancer Society
Zitieren
APA
Zou, T., Zhou, M., Gupta, A., Zhuang, P., Fishbein, A. R., Wei, H. Y., Capcha-Rodriguez, D., Zhang, Z., Cherniack, A. D., & Meyerson, M. (2024). XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. Cell Reports, 43(2), 113600. https://doi.org/10.1016/j.celrep.2023.113600
Vancouver
Zou T, Zhou M, Gupta A, Zhuang P, Fishbein AR, Wei HY, et al. XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells. Cell Reports. 2024;43(2):113600. doi:10.1016/j.celrep.2023.113600
BibTeX
@article{Zou2024,
author = {Zou, Tao and Zhou, Meng and Gupta, Akansha and Zhuang, Patrick and Fishbein, Alyssa R and Wei, Hope Y and Capcha-Rodriguez, Diego and Zhang, Zhouwei and Cherniack, Andrew D and Meyerson, Matthew},
title = {XRN1 deletion induces PKR-dependent cell lethality in interferon-activated cancer cells},
journal = {Cell Reports},
year = {2024},
volume = {43},
number = {2},
pages = {113600},
doi = {10.1016/j.celrep.2023.113600}
}
EUVIMED